Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Enhertu Gets Priority Review for HER2 Low or Ultralow Breast Cancer in US
October 2, 2024
- Pfizer Japan to Suspend Lower-Strength Version of Syphilis Drug
October 1, 2024
- Healios Again Delays Definitive MultiStem Deal with Nobelpharma
October 1, 2024
- Towa, SymBio/Eagle Settle Treakisym Patent Suit
October 1, 2024
- Nippon Kayaku Files Humira Biosimilar for nr-axSpA
October 1, 2024
- Astellas Touts Confirmed Safety and Antitumor Effects of Protein Degrader
September 30, 2024
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- 8 South Korean Biotechs Now Housed at Shonan iPark
September 30, 2024
- Shionogi Files Sage’s Depression Drug in Japan
September 30, 2024
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Fujirebio Files Blood-Based Diagnostic Test for Alzheimer’s in US
September 27, 2024
- Remitch OD Tablets Earns Indonesia Approval: Toray/Meiji Pharma
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- Nobelpharma Takes Nobelzin Patent Fight to IP High Court
September 27, 2024
- Santen Files Glaucoma Drug Sepetaprost in Japan
September 27, 2024
- Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
September 26, 2024
- J&J to Offer Rybrevant for Free until NHI Price Listing
September 26, 2024
- Daiichi Sankyo’s TROP2 ADC Misses OS Goal in Breast Cancer Trial
September 25, 2024
- No Major Physical Damages Seen with Wholesalers after Noto Downpours
September 25, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…